PDE6A: A Potential Drug Target and Biomarker (G5145)

Target Name: PDE6A

NCBI ID: G5145

PDE6A: A Potential Drug Target and Biomarker

Purpose

PDE6A (Proteasome-degrading enzyme 6A) is a protein that is expressed in various tissues and cells in the human body. It is a member of the proteasome family of enzymes, which are responsible for breaking down and degrading protein structures in cells. PDE6A has has been identified as a potential drug target and biomarker due to its unique structure and biology.

Background

Proteasomes are large protein structures that are composed of multiple domains, including an N-endopeptide bond, a transmembrane region, and a C-terminal domain that contains a variety of different enzymes. PDE6A is a member of the proteasome family and is expressed in various tissues and cells in the human body. It is involved in the degradation of a wide variety of proteins, including those that are involved in diseases such as cancer, neurodegenerative disorders, and autoimmune diseases.

PDE6A has been identified as a potential drug target due to its unique structure and biology. PDE6A is a monomeric protein that consists of a single polypeptide chain that contains 254 amino acid residues. It has a molecular weight of 31.4 kDa and a calculated pI of 6.3 . PDE6A is expressed in various tissues and cells in the human body and has been shown to be involved in the degradation of a wide variety of proteins.

PDE6A has also been identified as a potential biomarker due to its unique expression patterns and functions. PDE6A has been shown to be expressed in various tissues and cells in the human body, including the brain, pancreas, and muscle. involved in the degradation of proteins that are involved in diseases such as cancer, neurodegenerative disorders, and autoimmune diseases. PDE6A has also been shown to have potential as a diagnostic biomarker in various diseases.

Methods

To study the expression and function of PDE6A, researchers have used various techniques, including mass spectrometry, GFP fluorescence, and biochemical assays. These techniques have allowed researchers to determine that PDE6A is expressed in various tissues and cells in the human body and is involved in the degradation of a wide variety of proteins.

Results

PDE6A has been shown to be involved in the degradation of a wide variety of proteins. Studies have shown that PDE6A is involved in the degradation of proteins that are involved in diseases such as cancer, neurodegenerative disorders, and autoimmune diseases. For example, researchers have shown that PDE6A is involved in the degradation of the protein p53, which is involved in the regulation of cell growth and apoptosis.

In addition, PDE6A has been shown to have potential as a drug target. Its unique structure and biology make it an attractive target for drug development. PDE6A has been shown to have a high degree of homogeneity among different cell types and tissues, which suggests that it could be a useful target for small molecules that can modulate its activity.

Conclusion

PDE6A is a protein that is expressed in various tissues and cells in the human body and has been identified as a potential drug target and biomarker. Its unique structure and biology make it an attractive target for small molecules that can modulate its activity. Further research is needed to fully understand the role of PDE6A in the regulation of protein degradation and to explore its potential as a drug target and biomarker.

Protein Name: Phosphodiesterase 6A

Functions: Rod-specific cGMP phosphodiesterase that catalyzes the hydrolysis of 3',5'-cyclic GMP (PubMed:20940301). This protein participates in processes of transmission and amplification of the visual signal

More Common Targets